JEMPERLI (dostarlimab), a new programmed death receptor-1 (PD-1)-blocking antibody

[GP24]

Last year the FDA approved a drug that is an alternative for Keytruda (pembrolizumab). It is called Jemperli (dostarlimab-gxly) and offered by GlaxoSmithKline (GSK). The FDA approved it for patients with mismatch repair deficient recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.

The FDA also approved the VENTANA MMR RxDx Panel as a companion diagnostic device to select patients with mismatch repair deficient solid tumors for treatment with dostarlimab-gxly.

Only about 3 to 5 percent of prostate cancer patients have a mismatch repair deficient tumor. The approval was based on the Garnet trial which included a prostate cancer patient.

fda.gov/drugs/resources-inf...

gsk.com/en-gb/media/press-r...

If your insurance does not cover this treatment, you can take part in one of the current trials with dostarlimab.

clinicaltrials.gov/ct2/show...

clinicaltrials.gov/ct2/show...

clinicaltrials.gov/ct2/show...

clinicaltrials.gov/ct2/show...

clinicaltrials.gov/ct2/show...

Here are articles describing this new drug:

urologytimes.com/view/fda-g...

ncbi.nlm.nih.gov/pmc/articl...

ncbi.nlm.nih.gov/pmc/articl...

[Hidden]

Thanks for posting. I hope this will benefit some of our brethren here. Always good to hear of a treatment advancement.